Bristol Myers Squibb Stock In Focus

FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why I'm bullish on BMY heading into 2025.
Bristol-Myers Squibb Co (BMY) Stock Rated Buy by Jefferies
Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $57.68 which represents a decrease of $-0.32 or -0.55% from the prior close of $58. The stock opened at $57.65 and touched a low of $57.
(Nivolumab + relatlimab) by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong growth prospects and low valuation.
Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors
Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and
IL2-CD25 by Bristol-Myers Squibb for Autoimmune Disorders: Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders.
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment Brightens
Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an injectable version of the pharmaceutical major’s cancer drug Opdivo. Opdivo is reportedly part of PD-1 inhibitors class of drugs,
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
Best Stocks for 10 Years. In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands ...
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slumped 0.55% to $57.68 Friday, on what proved to be an all-around poor trading ...
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...
FiercePharma7d
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant Sotyktu
Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...
Bristol Myers Squibb Co. stock rises Monday, still underperforms market
Shares of Bristol Myers Squibb Co. BMY inched 0.44% higher to $57.58 Monday, on what proved to be an all-around favorable ...
Bristol-Myers Squibb's Long-term Dividend Outlook appears Promising
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/95.9f0PRuhz.js ...